ARMISTICE CAPITAL, LLC Acquires New Holdings in InMed Pharmaceuticals Inc
INM Stock | USD 4.97 0.17 3.54% |
About 55% of InMed Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading InMed Pharmaceuticals stock suggests that some investors are interested at this time. InMed Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in InMed Pharmaceuticals. Many technical investors use InMed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
InMed |
Overview of the Recent Transaction On September 30, 2024, ARMISTICE CAPITAL, LLC marked a significant portfolio addition by purchasing 34,81
Read at gurufocus.com
InMed Pharmaceuticals Fundamental Analysis
We analyze InMed Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InMed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InMed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
InMed Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
InMed Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with InMed Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of InMed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing InMed Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
InMed Pharmaceuticals Related Equities
ZVSA | ZyVersa Therapeutics | 13.76 | ||||
BDRX | Biodexa Pharmaceticals | 10.02 | ||||
VRAX | Virax Biolabs | 9.95 | ||||
SONN | Sonnet Biotherapeutics | 9.37 | ||||
ICU | LMF Acquisition | 7.69 | ||||
IMMX | Immix Biopharma | 6.82 | ||||
GOVX | GeoVax Labs | 6.45 | ||||
QNRX | Quoin Pharmaceuticals | 4.48 | ||||
PHIO | Phio Pharmaceuticals | 3.68 | ||||
PALI | Palisade Bio | 2.15 | ||||
REVB | Revelation Biosciences | 1.52 | ||||
NBY | NovaBay Pharmaceuticals | 1.59 | ||||
DRUG | Bright Minds | 3.06 | ||||
ALLR | Allarity Therapeutics | 4.50 | ||||
ATNF | 180 Life | 5.49 | ||||
TNXP | Tonix Pharmaceuticals | 6.06 |
Check out InMed Pharmaceuticals Hype Analysis, InMed Pharmaceuticals Correlation and InMed Pharmaceuticals Performance. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.